Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotiglipron (PF-07081532) DDI study with Midazolam, Omeprazole, and Oral Contraceptives in Obese Women
NCT05671653Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lotiglipron in obesity (2 cohorts), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time at Day 1 and Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration at Day 1. Started Jan 2023; status: terminated.
02
Drugs
lotiglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05671653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05671653.